Researchers assessed the accuracy of a traditional statistical risk factor-based model versus machine learning in predicting the 5-year probability of biologic discontinuation.
Study investigators assessed the risk of infection among pediatric patients undergoing treatment with methotrexate, etanercept, or ustekinumab for psoriasis.
A team of investigators sought to determine whether alcohol consumption or cigarette smoking contributed to the risk of developing psoriasis among postmenopausal women.
The researchers sought to evaluate whether there was an association between the presence of psoriasis and concomitant psoriatic arthritis and comorbidity burden and treatment outcomes.
Investigators sought to elucidate the prevalence of anxiety and depression in patients with pediatric psoriasis and advocate for psychological screening and intervention as needed.
The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.
AMA president Jack Resneck, Jr., MD, and dermatologist David M. Pariser, MD, FAAD, tell us their thoughts and experiences on the challenges patients face in accessing methotrexate for psoriasis and other autoimmune diseases.
Researchers sought to evaluate the impact of risankizumab vs placebo on health care-related quality of life and other patient-reported outcomes in patients with psoriatic arthritis.